Clinical trial
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not…
NCT00099970 · PDL BioPharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00099970 |
|---|---|
| Title | Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy |
| Official title | Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo |
| Lead sponsor | PDL BioPharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Metastases |
| Intervention type | Drug |
| Interventions | M200 (volociximab) in Combination with Dacarbazine (DTIC) |
| Enrollment | 40 |
| Start date | Dec 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Dec 22, 2004 |
| Last update posted | Aug 5, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: